Jeil Pharmaceutical Co.,Ltd

KSE 271980.KS

Jeil Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2023: USD 244.35 M

Jeil Pharmaceutical Co.,Ltd Current Liabilities is USD 244.35 M for the year ending December 31, 2023, a 15.13% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Jeil Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2022 was USD 212.24 M, a 14.25% change year over year.
Jeil Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2021 was USD 185.77 M, a -7.20% change year over year.
Jeil Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2020 was USD 200.18 M, a 11.37% change year over year.
Jeil Pharmaceutical Co.,Ltd Current Liabilities for the year ending December 31, 2019 was USD 179.74 M, a 3.34% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

KSE: 271980.KS

Jeil Pharmaceutical Co.,Ltd

CEO	Seok-Jae Sung
IPO Date	July 18, 2017
Location	South Korea
Headquarters	343, Sapyeong-daero
Employees	973
Sector	Consumers Staples
Industries Personal Care Baby & Childcare Cleaning Supplies Cosmetics Hardware & Electronics Non-Alcoholic Beverages Pharmaceuticals Plastics

Description

Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company also exports its products to approximately 40 countries in ASEAN, Central and South America, Africa, and internationally. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years